Natixis Advisors LLC Buys 6,545 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Natixis Advisors LLC raised its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 56.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,184 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,545 shares during the period. Natixis Advisors LLC owned 0.09% of ANI Pharmaceuticals worth $1,085,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in ANIP. Innealta Capital LLC purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $65,000. Ridgewood Investments LLC bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at approximately $85,000. SG Americas Securities LLC purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $106,000. XTX Topco Ltd bought a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at approximately $207,000. Finally, O Shaughnessy Asset Management LLC purchased a new stake in ANI Pharmaceuticals during the 1st quarter valued at $218,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on ANIP. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Piper Sandler assumed coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. Finally, Raymond James boosted their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $77.33.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $57.86 on Wednesday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a market cap of $1.22 billion, a P/E ratio of -105.29 and a beta of 0.71. The firm’s 50 day moving average price is $58.36 and its 200-day moving average price is $60.83. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.05 EPS. As a group, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.